Medullary Thyroid Cancer Survival Rate by Stage

Five-year survival for medullary thyroid cancer (MTC) ranges from roughly 97% in stage I down to about 74% in stage IV, though the numbers vary depending on which study and which staging edition you look at. One large U.S. population-based analysis reported five-year survival of 97.0%, 92.6%, 91.2%, and 73.6% for stages I through IV, respectively.¹ Those numbers look encouraging compared with many cancers, but they obscure enormous variation within each stage, and the ten-year picture shifts in ways that surprise most people.

Five-Year Survival by Stage

MTC is staged using the TNM system, which groups patients based on tumor size, lymph node involvement, and whether the cancer has spread to distant organs. The most frequently cited five-year survival numbers come from analyses of the U.S. SEER (Surveillance, Epidemiology, and End Results) database and validated staging cohorts. In a clinical validation of the eighth-edition TNM staging, five-year cancer-specific survival was 100% for both stage I and stage II, about 96% for stage III, and roughly 85% for stage IV.² A separate national analysis that measured overall survival rather than cancer-specific survival found slightly lower figures: 97% for stage I, about 93% for stage II, 91% for stage III, and 74% for stage IV.¹

These two sets of numbers differ for a straightforward reason. Cancer-specific survival counts only deaths caused by MTC, while overall survival counts deaths from any cause. Since MTC tends to strike in middle age and many patients live with the disease for years, some die of heart disease or other conditions rather than their cancer. Both measures are useful: cancer-specific survival tells you the threat from MTC itself, while overall survival tells you what your life expectancy actually looks like once you have the diagnosis.

The stage IV category deserves special attention because it lumps together very different situations. Patients with locally advanced tumors in the neck (stage IVA or IVB) have meaningfully better odds than patients whose cancer has spread to distant organs like the lungs, liver, or bones (stage IVC). A study focused specifically on stage IVC patients found five-year overall survival of only about 32% and five-year cancer-specific survival of roughly 40%.³ That gap between “stage IV overall” and “stage IVC specifically” is one reason published survival rates can be misleading if you don’t know which subgroup they represent.

Ten-Year Survival and Why the Numbers Shift

MTC’s ten-year survival figures reveal something the five-year numbers hide. In the eighth-edition TNM validation study, ten-year cancer-specific survival was 100% for stage I, about 92% for stage II, roughly 55% for stage III, and about 80% for stage IV.² That stage III figure is jarring: how can ten-year survival for stage III be lower than for stage IV? The issue is a known quirk of how the standard staging system groups patients. Certain node-positive patients classified as stage III in this cohort had particularly aggressive biology, while some patients classified as stage IV (based on local extension alone) actually had more indolent disease.

The researchers recognized this problem and applied a statistical regrouping method. After reclassification, the five-year cancer-specific survival figures fell into a cleaner stepwise pattern: 100% for stage I, about 98% for stage II, roughly 82% for stage III, and 25% for stage IV.² That reclassified stage IV figure of 25% at five years far more closely matches the reality for patients with distant metastases, while the reclassified stage III figure of 82% better reflects what node-positive but non-metastatic patients actually experience.

Across all stages combined, a large multicenter study of 899 patients found an overall adjusted survival of about 86% at five years and 78% at ten years.⁴ For context, a population-based analysis comparing thyroid cancer subtypes found ten-year survival of about 74% for medullary thyroid cancer, compared with roughly 88% for papillary and 80% for follicular types.⁵ MTC is rarer and more aggressive than the common thyroid cancer subtypes, which is why it receives so much attention despite accounting for a small fraction of all thyroid cancers.

Age, Sex, and Other Factors That Shape Prognosis

Stage and age at diagnosis are consistently the two strongest predictors of survival in MTC. In a study of over 1,200 patients, having advanced disease carried a hazard ratio of about 4.5, while being older than 65 at diagnosis carried a hazard ratio of roughly 6.6, meaning older patients had more than six times the risk of dying compared with younger patients at the same stage.⁶ Women younger than 40 with early-stage disease tend to have the best outcomes of all.⁷

Male sex has emerged as an independent risk factor in several analyses. One study found that men had worse survival even after adjusting for age, the presence of distant metastases, and other adverse features.⁸ Whether this reflects underlying biology or differences in how and when men seek medical care remains an open question. A separate large dataset similarly confirmed male sex as protective when absent and detrimental when present, even in multivariate models.⁹

The number of lymph nodes involved also matters significantly. Data from a national cohort showed that patients who had their cervical lymph nodes removed and found negative had about 90% survival, while patients with 16 or more positive nodes had survival around 55%.¹⁰ The ratio of positive nodes to total nodes removed has also been validated as an independent predictor of disease-free survival, with high-ratio patients having roughly five times the risk of recurrence compared with low-ratio patients.¹¹

Calcitonin Levels and Doubling Times

MTC arises from the C cells of the thyroid, which produce the hormone calcitonin. This gives doctors a blood marker they can track after surgery to gauge how the disease is behaving. Two measurements matter most: postoperative calcitonin levels and how fast calcitonin (or a related marker called CEA) is rising over time, expressed as the “doubling time.”

Achieving undetectable calcitonin after surgery is the strongest sign of a good outcome. One large retrospective study found that patients who failed to achieve this biochemical remission had dramatically higher recurrence risk.¹² The 899-patient multicenter study found that patients who achieved biochemical cure had a ten-year survival of about 98%.⁴ But “normalized” calcitonin is not the same as “undetectable,” and the distinction matters. Patients whose calcitonin fell to within the normal range but remained detectable had a 25% risk of disease recurrence, compared with only 3% in patients whose calcitonin became truly undetectable.¹³

Doubling time turns out to be one of the most powerful prognostic tools available. A meta-analysis found that patients whose calcitonin doubled in under a year had vastly higher risks of both dying and recurring compared with patients whose doubling time exceeded a year. CEA doubling time was even more predictive than calcitonin doubling time when both markers were available.¹⁴ In practice, a patient with slowly rising calcitonin after surgery may live for decades with stable or slowly progressive disease, while someone whose calcitonin doubles every few months likely faces an aggressive course. Tumor grade adds another layer: high-grade MTC patients are far more likely to have short doubling times, and on multivariate analysis, high tumor grade independently predicted worse local recurrence, distant spread, and overall survival even after accounting for doubling time.¹⁵

Hereditary Versus Sporadic MTC

About a quarter of MTC cases are hereditary, linked to inherited mutations in the RET gene and occurring as part of familial syndromes such as multiple endocrine neoplasia type 2 (MEN2). The remaining cases are sporadic, meaning they arise without a known inherited mutation. At first glance, hereditary cases seem to have better survival: one French registry study found five-year survival of 95% for hereditary MTC versus 82% for sporadic MTC.¹⁶

But this survival gap is almost certainly an artifact of how the two groups are diagnosed. Families with known RET mutations are screened early and often, which catches tumors at earlier stages. When researchers compared sporadic and hereditary MTC patients at the same stage, the survival differences largely disappeared.⁹ A Korean study with 30 years of follow-up data reported no significant difference in overall or progression-free survival between sporadic and hereditary groups.¹⁷ The lesson is that early detection, not the type of MTC, drives the survival advantage in hereditary cases.

In sporadic cases, acquired (somatic) RET mutations are a different story. A ten-year follow-up study found that sporadic MTC patients whose tumors harbored somatic RET mutations had worse outcomes, and the presence of a somatic RET mutation was independently associated with survival even after adjusting for stage.¹⁸ Somatic RET mutations tended to appear in larger tumors with more node and distant metastases, suggesting they mark a more biologically aggressive form of the disease.¹⁹

How Surgery Shapes Outcomes

Surgery remains the only curative treatment for MTC. The standard operation is total thyroidectomy with dissection of the central lymph node compartment in the neck. Current guidelines recommend that when disease involves lateral neck nodes, the involved compartment should be dissected, and if preoperative calcitonin is above 200 pg/mL, surgeons should also consider removing the nodes on the opposite side of the neck even if imaging looks clean there.²⁰ The rationale is that elevated calcitonin predicts a higher likelihood of occult nodal disease that imaging may miss.²¹

What matters for survival depends partly on tumor size and the presence of distant metastases. In patients with tumors 2 cm or smaller and no distant spread, the type of surgical intervention did not significantly affect survival. But in patients with tumors larger than 2 cm and no distant spread, all forms of surgery improved survival compared with no surgery. And among patients who already had distant metastases at presentation, only total thyroidectomy combined with regional lymph node removal significantly improved survival.¹⁰

Recurrence after initial surgery is not uncommon. About 23% of patients in one large surgical series developed cervical lymph node recurrence, with the median time to recurrence being roughly two years after the first operation. The strongest predictor of recurrence was having pathologically involved lymph nodes at the initial surgery, while achieving biochemical cure afterward was strongly protective.²² Most patients who recurred in the neck underwent repeat surgery. Local recurrence, interestingly, did not appear to worsen overall survival in that series, suggesting that re-operation can effectively manage many cases of regionally recurrent disease.

Timing of surgery also appears to matter. MTC is sometimes diagnosed incidentally after a patient has surgery for what was thought to be a different type of thyroid nodule, which happens in roughly 10–15% of cases.²³ A recent study found that surgical delays of two months or longer were associated with tumor progression, increased lymph node involvement, and poorer overall survival.²⁴

Drug Treatments for Advanced and Metastatic MTC

When MTC has spread beyond the reach of surgery, systemic therapy enters the picture. The mainstays are tyrosine kinase inhibitors (TKIs), which block signals that drive tumor growth. Two TKIs have long been approved specifically for MTC: vandetanib and cabozantinib. Vandetanib improved progression-free survival to about 30.5 months compared with roughly 19.3 months in controls.²⁵ Cabozantinib showed meaningful tumor shrinkage in early trials, with about 29% of measurable-disease patients achieving a partial response and another 41% maintaining stable disease for six months or more.²⁶

A systematic review and meta-analysis of TKI use in MTC estimated a pooled progression-free survival of about 23 months across studies.²⁷ These drugs do not cure the cancer, but they can meaningfully slow its progression. More recently, selective RET inhibitors such as selpercatinib and pralsetinib have been approved, targeting the specific molecular driver behind many MTC cases. These newer agents tend to be better tolerated than vandetanib and cabozantinib, which carry side effects including diarrhea, skin reactions, hypertension, and fatigue that can substantially affect quality of life. The decision of when to start systemic therapy involves weighing the pace of disease progression against treatment side effects, since some patients with stable or slowly growing metastatic MTC may be watched for months or years before treatment becomes necessary.

Personalized Prediction Tools

One limitation of TNM staging is that it collapses many variables into a single stage label. Two stage III patients may have very different prognoses based on their age, calcitonin doubling time, number of positive lymph nodes, and tumor grade. Researchers have developed nomograms, which are statistical tools that weigh multiple factors simultaneously to generate an individualized survival estimate.

Several nomograms built specifically for MTC have outperformed the TNM staging system in predicting survival.²⁸ One early nomogram for MTC demonstrated that this statistical approach avoids the bias of relying on any single clinical variable and makes risk quantification accessible to both patients and clinicians.²⁹ A more recent model using advanced variable-selection techniques achieved concordance indices above 0.81, compared with about 0.72 for standard TNM staging alone, meaning it correctly ranked patients’ risk more than four times out of five.³⁰

These tools are not yet standard in every clinic, but they represent the direction that MTC prognostication is heading. For a patient trying to understand what a stage label means for them personally, a nomogram that incorporates their specific age, calcitonin trajectory, lymph node burden, and tumor characteristics will give a more accurate picture than any stage-based survival table can.

When Survival Tables Get It Wrong

Stage-based survival numbers are population averages, and for MTC they can be misleading in several specific ways. The most common pitfall is failing to distinguish between cancer-specific survival and overall survival. For a 35-year-old with stage II MTC, the cancer-specific survival rate is essentially 100% at five years, and overall survival is nearly the same because that person is young and otherwise healthy. For a 70-year-old with the same stage, cancer-specific survival is still excellent, but overall survival may be lower simply because of competing health risks. Both patients have stage II disease, but their real-world life expectancies differ considerably.

Another common misunderstanding involves the word “cure.” MTC can produce measurable calcitonin for years or even decades after surgery without causing symptoms or shortening life. Some patients live with persistently elevated calcitonin and no detectable structural disease on imaging for their entire lives. Others see a slow, steady rise that eventually leads to detectable metastases. The biology of MTC runs the full spectrum from extremely indolent to rapidly fatal, and stage alone does not tell you where a given patient falls on that spectrum. This is why calcitonin doubling time and tumor grade have emerged as such valuable supplements to staging: they capture the tumor’s behavior, not just its geography.

People who receive an MTC diagnosis should also be aware that the published survival statistics reflect patients treated over many years, some going back decades. Treatment has improved steadily, with better surgical techniques, more refined imaging, the arrival of targeted drugs, and molecular profiling that helps guide therapy. The survival rate for someone diagnosed today is likely somewhat better than what historical databases report, though the degree of improvement is hard to quantify precisely because MTC’s rarity limits the size and speed of clinical trials.